drug molecules such as the serotonin 1A receptor antagonist
LY426965, and (-)-phenserine, a candidate for the treatment
of Alzheimer’s disease.7,8 Ketoketene dimers are potential
enzyme inhibitors, and such investigations of biological activity
are currently in progress at our laboratory.4
Some time ago, Elam and, shortly after, Bentrude showed
that dimethylketene could be dimerized using trialkyl phosphites
as nucleophilic catalysts.5 However, following these examples
of catalytic ketoketene dimerization, no general system and no
study of stereoselectivity has emerged in the intervening years.
More recently, Calter showed that a nucleophilic catalyst system
(TMS-quinine or TMS-quinidine) could catalyze the dimeriza-
tion of alkyl-substituted aldoketenes with high enantioselectiv-
ity.3
Organocatalytic Dimerization of Ketoketenes
Ahmad A. Ibrahim, Gero D. Harzmann, and
Nessan J. Kerrigan*
Department of Chemistry, Oakland UniVersity, 2200 North
Squirrel Road, Rochester, Michigan 48309-4477
ReceiVed NoVember 5, 2008
SCHEME 1. Nucleophile-Catalyzed Dimerization of
Methylphenylketene
A general method for the catalytic dimerization of ke-
toketenes is described. Tri-n-butylphosphine was found to
be the optimal organocatalyst for the racemic reaction. When
lithium iodide was used as an additive, the reaction was rendered
selective for dimer formation (dimer/trimer g16:1). Ring-
opening reactions of the ketoketene dimers as well as
preliminary studies toward the development of an asymmetric
variant are also reported.
We initiated a study of methylphenylketene dimerization by
investigating the alkaloid catalytic systems previously described
by other groups for various [2 + 2]-cycloadditions involving
ketenes.3,9,10 However, only low conversion (<10%) to ke-
toketene dimer was observed with this class of nucleophilic
catalysts (Scheme 1). Inspired by the precedent of Elam’s work,
we proceeded to investigate tricoordinate phosphorus catalysts
for their activity toward methylphenylketene. Tri-n-butylphos-
phine was found to be the most effective of all the catalysts
surveyed (Table 1, entry 1). At this point, the reaction afforded
a mixture of products including the desired ketoketene dimer
product 4a (58% conversion) as well as ketoketene trimer 5a
(42% conversion). Interestingly, no formation of trimer as a
side product had been encountered by Calter’s group when they
reported the TMS-quinine catalyzed dimerization of meth-
ylketene.3
ꢀ-Lactones are interesting targets in synthesis as they are
versatile intermediates and are integral structural features of a
number of biologically active molecules, such as (-)-panclicin
D and 1233A.1,2 While aldoketene dimer ꢀ-lactones have been
used extensively in synthetic activities by Calter and co-workers,
ketoketene dimers have received less attention due to the paucity
of general methods for their preparation.3-5 Ketoketene dimers
are among the most interesting ꢀ-lactones from a reactivity
standpoint due to the presence of an exocyclic double bond with
potential for use as a nucleophile following ring-opening
reactions.6 In addition, ꢀ-lactone ketene dimers have recently
been shown to have activity as enzyme active site inhibitors by
Romo and co-workers.4
As part of our program of studies toward the development
of new reactions involving phosphonium enolates, we sought
to develop an efficient methodology for the dimerization of
ketoketenes. We anticipate that the ketoketene dimers may
provide access to the quaternary stereogenic center of interesting
The lack of dimer selectivity in the PBu3 system may be due
to the enhanced reactivity of the phosphonium enolate inter-
mediates compared to the ammonium enolate species encoun-
tered in TMS-quinine catalyzed reactions.3 We therefore
(1) Yang, H. W.; Romo, D. J. Org. Chem. 1997, 62, 4.
(2) Dymock, B. W.; Kocienski, P. J.; Pons, J.-M. Synthesis 1998, 1655.
(3) Calter, M. A. J. Org. Chem. 1996, 61, 8006. Calter, M. A.; Orr, R. K.
Org. Lett. 2003, 5, 4745.
(4) Purohit, V. C.; Richardson, R. D.; Smith, J. W.; Romo, D. J. Org. Chem.
2006, 71, 4549.
(7) Rasmussen, K.; Calligaro, D. O.; Czachura, J. F.; Dreshfield-Ahmad, L. J.;
Evans, D. C.; Hemrick-Luecke, S. K.; Kallman, M. J.; Kendrick, W. T.; Leander,
J. D.; Nelson, D. L.; Overshiner, C. D.; Wainscott, D. B.; Wolff, M. C.; Wong,
D. T.; Branchek, T. A.; Zgombick, J. M.; Xu, Y.-C. J. Pharmacol. Exp. Ther.
2000, 294, 688.
(8) Huang, A.; Kodanko, J. J.; Overman, L. E. J. Am. Chem. Soc. 2004,
126, 14043.
(9) Taggi, A. E.; Hafez, A. M.; Wack, H.; Young, B.; Ferraris, D.; Lectka,
T. J. Am. Chem. Soc. 2002, 124, 6626.
(10) Zhu, C.; Shen, X.; Nelson, S. G. J. Am. Chem. Soc. 2004, 126, 5352.
(5) Hasek, R. H.; Clark, R. D.; Elam, E. U.; Martin, J. C. J. Org. Chem.
1962, 27, 60. Elam, E. U. J. Org. Chem. 1967, 32, 215. Bentrude, W. G.; Johnson,
W. D. J. Am. Chem. Soc. 1968, 90, 5924. Aronov, Y. E.; Cheburkov, Y. A.;
Knunyants, I. L. IzV. Akad. Nauk SSSR, Ser. Khim. 1967, 8, 1758. Moore, H. W.;
Duncan, W. G. J. Org. Chem. 1973, 38, 156.
(6) Calter, M. A.; Song, W.; Zhou, J. J. Org. Chem. 2004, 69, 1270.
10.1021/jo8024785 CCC: $40.75
Published on Web 01/16/2009
2009 American Chemical Society
J. Org. Chem. 2009, 74, 1777–1780 1777